Vanda Pharmaceuticals | VNDA - Current Assets


Vanda Pharmaceuticals reported $347.26M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Akebia Therapeutics USD 229.55M 13.93M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Halozyme Therapeutics USD 933.02M 70.01M Jun/2026
Heron Therapeutics USD 229.84M 861K Jun/2026
Insmed USD 1.63B 20.75M Jun/2026
J&J USD 59.77B 601M Jun/2026
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
Ligand Pharmaceuticals USD 1.46B 591.7M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Moderna USD 5.82B 45M Jun/2026
Novartis USD 26.61B 3.85B Mar/2026
Pfizer USD 41.36B 1.46B Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 31.52B 1.36B Jun/2026
Takeda JPY 3.15T 59.77B Jun/2026
Teva Pharmaceutical Industries USD 13.76B 50M Jun/2026
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Veracyte USD 574.78M 52.6M Jun/2026